## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2022-09-28_Virtual Town Hall 93_fixnames.md
last updated: 2025-01-05 Created QA Sections
link pdf: https://www.fda.gov/media/162060/download?attachment
link youtube: https://youtu.be/R43Hd0KnIhs
link slides: https://www.fda.gov/media/162061/download?attachment
topic: COVID-19 and Monkeypox


## content

### qa


#### 1. Monkeypox and COVID-19 Diagnostic Test Updates

QA Block 1-1
CLARIFIED QUESTION: What are the steps required for monkeypox LDT developers to notify the FDA by the October 13 deadline?
CLARIFIED ANSWER: Monkeypox LDT developers must send an email notification to FDA by October 13th, 30 days after the monkeypox test policy guidance publication. The notification applies to validated single-site PCR tests using lesion swab samples without submitting additional data or an EUA request.
VERBATIM QUESTION: What are the steps required for monkeypox LDT developers to notify the FDA by the October 13 deadline?
VERBATIM ANSWER: First up is a reminder of the October 13 '22 deadline for the monkeypox. It is 30 days. That date is 30 days after the publication of the monkeypox test policy guidance. This is the deadline for both LDT notifications to be sent to the FDA and also for experienced developers, kit test developers, who informed FDA by email of their intent to submit an EUA request for a monkeypox diagnostic test. So that's the first key important update is to be aware of date. The second update is that primarily for monkeypox LDT developers. I'd like to remind callers today that the FDA does not expect an EUA request for certain validated monkeypox diagnostic LDT tests that are developed and performed in a single app that use PCR and the only sample size is lesion swab samples. Lesion swab samples are broadly defined as any swab from a lesion that could be monkeypox. FDA just expects a notification by email with no data, no review, no decision by the FDA on an application, and then no EUA authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Monkeypox LDT notification, FDA deadline, EUA process
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: Are there circumstances where an EUA request is not expected for monkeypox diagnostic tests?
CLARIFIED ANSWER: The FDA does not expect an EUA request for validated monkeypox LDTs performed in a single app using PCR with lesion swab samples as the only sample type. Only email notification is required without data, review, or EUA authorization.
VERBATIM QUESTION: Are there circumstances where an EUA request is not expected for monkeypox diagnostic tests?
VERBATIM ANSWER: The FDA does not expect an EUA request for certain validated monkeypox diagnostic LDT tests that are developed and performed in a single app that use PCR and the only sample size is lesion swab samples. Lesion swab samples are broadly defined as any swab from a lesion that could be monkeypox. FDA just expects a notification by email with no data, no review, no decision by the FDA on an application, and then no EUA authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA exemptions for monkeypox tests, FDA notification requirements
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: What is the FDA's enforcement discretion policy for monkeypox LDTs after the EUA test declaration?
CLARIFIED ANSWER: The FDA applies a narrow enforcement discretion policy for monkeypox single-site PCR lesion swab LDTs both before and after the EUA test declaration.
VERBATIM QUESTION: What is the FDA's enforcement discretion policy for monkeypox LDTs after the EUA test declaration?
VERBATIM ANSWER: Outside of a declared emergency and prior to the EUA test declaration for monkeypox, the FDA generally has to exercise enforcement discretion for LDT. And for this subset of monkeypox diagnostic tests, single-site PCR lesion swab, the FDA has also implemented a narrow policy of enforcement discretion after the EUA test declaration.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Monkeypox LDTs, Enforcement Discretion, EUA Declaration
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: What are the appropriate uses of the CDC-cleared NVO orthopox assay for validating monkeypox tests?
CLARIFIED ANSWER: The FDA recommends using contrived or clinical samples for monkeypox test validation. The CDC-cleared NVO assay may provide leftover samples for validation, but its primary use should be for diagnostic testing.
VERBATIM QUESTION: What are the appropriate uses of the CDC-cleared NVO orthopox assay for validating monkeypox tests?
VERBATIM ANSWER: The FDA's current validation recommendations for monkeypox diagnostic tests include the use of contrived samples when it may be difficult to obtain positive clinical samples for validation. If you have access to clinical samples, you may validate using your clinical agreement study with an appropriate comparator as described in the template. As discussed in the town hall last week, the CDC performed by the LRN labs and the five commercial labs that are currently the only-- and that test is currently the only appropriate comparator until we have additional EUA authorizations that make additional appropriate comparators available. The CDC has asked that their tests primarily be reserved for diagnostic testing, not validation of testing. The laboratories performing the CDC assay may provide leftover samples, including the test results and Ct or cycle threshold values that are outputted by the cleared test that other test developers can use for validation. So we are encouraging that if you want to validate using real samples that you obtain samples that have been tested with the CDC NVO cleared assay. However, we are not recommending asking those laboratories to use the CDC to test clinical samples you may have acquired elsewhere since the testing will be potentially solely for assay validation and not to diagnose the patient.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CDC NVO assay use, Monkeypox test validation, Diagnostic vs validation use
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: Can laboratories provide leftover CDC NVO assay tested samples for validation purposes?
CLARIFIED ANSWER: Laboratories performing the CDC assay can provide leftover samples, including test results and Ct values, for validation purposes. FDA encourages obtaining samples tested with the CDC NVO cleared assay for validation.
VERBATIM QUESTION: Can laboratories provide leftover CDC NVO assay tested samples for validation purposes?
VERBATIM ANSWER: The laboratories performing the CDC assay may provide leftover samples, including the test results and Ct or cycle threshold values that are outputted by the cleared test that other test developers can use for validation. So we are encouraging that if you want to validate using real samples that you obtain samples that have been tested with the CDC NVO cleared assay.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CDC NVO assay, Validation samples, Leftover samples
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: Are test developers allowed to request new clinical samples to be tested with the CDC assay for validation purposes?
CLARIFIED ANSWER: FDA encourages using leftover samples tested with the CDC assay but advises against requesting new tests solely for assay validation.
VERBATIM QUESTION: Are test developers allowed to request new clinical samples to be tested with the CDC assay for validation purposes?
VERBATIM ANSWER: The FDA's current validation recommendations for monkeypox diagnostic tests include the use of contrived samples when it may be difficult to obtain positive clinical samples for validation. If you have access to clinical samples, you may validate using your clinical agreement study with an appropriate comparator as described in the template. As discussed in the town hall last week, the CDC performed by the LRN labs and the five commercial labs that are currently the only-- and that test is currently the only appropriate comparator until we have additional EUA authorizations that make additional appropriate comparators available. The CDC has asked that their tests primarily be reserved for diagnostic testing, not validation of testing. The laboratories performing the CDC assay may provide leftover samples, including the test results and Ct or cycle threshold values that are outputted by the cleared test that other test developers can use for validation. So we are encouraging that if you want to validate using real samples that you obtain samples that have been tested with the CDC NVO cleared assay. However, we are not recommending asking those laboratories to use the CDC to test clinical samples you may have acquired elsewhere since the testing will be potentially solely for assay validation and not to diagnose the patient.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CDC assay usage, Sample validation, Monkeypox diagnostic development
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: What should developers know about the recent updates to the COVID test policy guidance issued on September 27th?
CLARIFIED ANSWER: The COVID test policy was updated on September 27th to reduce priorities for EUA request reviews and to recommend a shift to traditional premarket review pathways for COVID-19 test types. Resources like the press release and updated FAQs are available.
VERBATIM QUESTION: What should developers know about the recent updates to the COVID test policy guidance issued on September 27th?
VERBATIM ANSWER: Yesterday, September 27th, we did update the COVID test policy. There's a link on this slide to the press release and to the reissued guidance as well as updated frequently asked questions that may be helpful for developers who are looking to see how things will be handled moving forward. So the main point of this guidance update was to indicate new reduced priorities for reviewing EUA requests for COVID and to encourage developers to seek traditional premarket review for most COVID-19 test types.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: COVID test policy update, EUA request changes, Premarket review pathways
REVIEW FLAG: False

QA Block 1-8
CLARIFIED QUESTION: Which types of COVID-19 diagnostic tests are now prioritized for EUA review by the FDA?
CLARIFIED ANSWER: The FDA is prioritizing EUA review for COVID-19 diagnostic tests that have significant public health benefits, address unmet needs, or involve supplemental requests fulfilling authorization conditions or significant public health modifications. Additionally, requests supported by U.S. government stakeholders will also be reviewed.
VERBATIM QUESTION: Which types of COVID-19 diagnostic tests are now prioritized for EUA review by the FDA?
VERBATIM ANSWER: So these are the types of COVID-19 tests that we do intend to focus our review. And generally, that's going to be EUA requests and supplemental EUA requests, so supplements to previously authorized tests, that are for diagnostic tests likely to have a significant benefit to public health, diagnostic tests that are likely to fulfill an unmet need. And then for supplemental requests, so modifications, those will be when the request is intended to fulfill a condition of authorization or if the modification would significantly benefit public health or fulfill an unmet need. And then as before, we will continue to review EUA requests that are from or supported by a US government stakeholder.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: COVID-19 EUA prioritization, Test benefit and unmet needs, Supplemental requests
REVIEW FLAG: False

QA Block 1-9
CLARIFIED QUESTION: What does the FDA recommend for developers considering the traditional premarket review pathway?
CLARIFIED ANSWER: The FDA encourages developers to consider traditional premarket review pathways (510(k) or de novo) and emphasizes the higher evidence requirements compared to EUAs. Developers are advised to submit pre-submissions to discuss validation approaches and seek specific recommendations via email or pre-sub meetings. Developers unsure about their review priorities should contact the FDA.
VERBATIM QUESTION: What does the FDA recommend for developers considering the traditional premarket review pathway?
VERBATIM ANSWER: And then beyond that, we are encouraging the use of the traditional premarket review pathways. So as I mentioned before, that's de novo and 510k. And then it's important to note that the statutory requirements for the level of evidence for authorization under a traditional premarket review pathway is higher than the statutory requirements for emergency use authorization. So we would encourage you to submit a pre-submission to discuss your validation approaches. And we can also provide recommendations that are specific to a test developer situation. And we can do that both by email if they're simple questions or through pre-Subs for the more complex questions. And if you're unsure whether your test may be prioritized for review or if you should consider a traditional premarket review pathway, we encourage you to reach out through the mailbox to have that discussion.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Traditional premarket review, FDA recommendations, Validation approaches
REVIEW FLAG: False

QA Block 1-10
CLARIFIED QUESTION: What is the distinction between EUA statutory requirements and traditional premarket approval requirements?
CLARIFIED ANSWER: The statutory requirements for the level of evidence are higher for traditional premarket review pathways than for emergency use authorization.
VERBATIM QUESTION: What is the distinction between EUA statutory requirements and traditional premarket approval requirements?
VERBATIM ANSWER: It's important to note that the statutory requirements for the level of evidence for authorization under a traditional premarket review pathway is higher than the statutory requirements for emergency use authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA vs. traditional premarket approval, regulatory requirements
REVIEW FLAG: False

QA Block 1-11
CLARIFIED QUESTION: What are the conditions under which modified COVID-19 diagnostic tests require a new EUA or traditional authorization?
CLARIFIED ANSWER: Modified COVID-19 diagnostic tests generally require a new EUA or traditional marketing authorization unless the modification was made under previous policies, fulfills a condition of authorization, or certain validated modifications by high complexity CLIA labs. FDA encourages traditional premarket review for modifications beyond prioritized scopes.
VERBATIM QUESTION: What are the conditions under which modified COVID-19 diagnostic tests require a new EUA or traditional authorization?
VERBATIM ANSWER: In general, we now expect modified tests to be authorized under an EUA or a traditional marketing authorization before being distributed or offered. We generally don't intend to object to continued implementation during FDA review for modifications that were made prior to yesterday's guidance update under the policies that were in the previous version of the guidance. And we also continue to not object to implementation without a new EUA of certain validated modifications made by a high complexity CLIA certified laboratory to an authorized COVID-19 diagnostic test. So that is similar to the policy that has been in place in previous versions of the guidance. We do, as I mentioned, intend to review supplements for previously authorized tests when the request is intended to fulfill a condition of authorization or when the modification is within the priorities that are outlined in the guidance. And then some modifications that are beyond the scope of the priorities, we encourage submitting that modification through the traditional premarket review pathway.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Modified COVID-19 tests, EUA requirements, Premarket review
REVIEW FLAG: False

QA Block 1-12
CLARIFIED QUESTION: For ongoing EUA reviews, how does the FDA handle unauthorized COVID-19 diagnostic tests already being marketed or distributed?
CLARIFIED ANSWER: The FDA generally allows unauthorized COVID-19 tests under review to continue being distributed if they were previously listed on notification lists or submitted as EUA requests. However, developers must cease distribution within 15 calendar days if the FDA declines review or authorization.
VERBATIM QUESTION: For ongoing EUA reviews, how does the FDA handle unauthorized COVID-19 diagnostic tests already being marketed or distributed?
VERBATIM ANSWER: We are generally continuing to not intend to object, which means that we don't have any concern with the continued distribution or offering of the test while under FDA review. And that's for tests that are on one of the notification lists on our website at the time of issuance of the guidance, so as of yesterday as well as the LDTs that were offered prior to November 15, 2021 where an EUA request was submitted to FDA under that policy described in that 2021 version of the guidance. So those are the EUA requests that should have been received by January of 2022. And then generally, we expect that developers have or will cease distributing, marketing, and offering their tests within 15 calendar days if they receive a notice from FDA that we declined to review, declined to issue, or otherwise declined or decide not to authorize the test for any reason.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA reviews, Unauthorized COVID-19 tests, FDA review policies
REVIEW FLAG: False

QA Block 1-13
CLARIFIED QUESTION: What is the FDA's policy for high-complexity CLIA labs making validated modifications to an existing authorized COVID-19 test?
CLARIFIED ANSWER: The FDA allows high-complexity CLIA labs to implement certain validated modifications to an existing authorized COVID-19 test without requiring a new EUA, consistent with prior policies.
VERBATIM QUESTION: What is the FDA's policy for high-complexity CLIA labs making validated modifications to an existing authorized COVID-19 test?
VERBATIM ANSWER: And we also continue to not object to implementation without a new EUA of certain validated modifications made by a high complexity CLIA certified laboratory to an authorized COVID-19 diagnostic test. So that is similar to the policy that has been in place in previous versions of the guidance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA lab modifications, COVID-19 test authorization
REVIEW FLAG: False

QA Block 1-14
CLARIFIED QUESTION: When and how should developers cease distribution or marketing if their EUA request is declined by the FDA?
CLARIFIED ANSWER: FDA expects developers to stop distributing, marketing, and offering tests within 15 calendar days if their EUA request is declined or review is not authorized.
VERBATIM QUESTION: When and how should developers cease distribution or marketing if their EUA request is declined by the FDA?
VERBATIM ANSWER: generally, we expect that developers have or will cease distributing, marketing, and offering their tests within 15 calendar days if they receive a notice from FDA that we declined to review, declined to issue, or otherwise declined or decide not to authorize the test for any reason.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA requests, Test distribution cessation
REVIEW FLAG: False


#### 2. Guidance for Submitting Monkeypox EUA Requests to FDA

QA Block 2-1
CLARIFIED QUESTION: Can monkeypox diagnostic test developers inform FDA of their intent to submit an EUA request without providing a timeline for completion of validation studies and submission of an EUA request?
CLARIFIED ANSWER: FDA recommends, but does not require, developers to include preliminary information such as the test description, manufacturing capacity, validation data, and a timeline for development and EUA submission, as this supports prioritization efforts.
VERBATIM QUESTION: Can monkeypox diagnostic test developers inform FDA of their intent to submit an EUA request without providing a timeline for completion of validation studies and submission of an EUA request?
VERBATIM ANSWER: So as discussed in the monkeypox test policy guidance, FDA generally recommends including certain preliminary information in the test developer's email to FDA to indicate their intent to submit an EUA request for a monkeypox diagnostic test. So that information includes the description of the test technology, manufacturing capacity, test throughput, any available validation data, and the expected timeline for development validation and submission of an EUA request. While these are recommendations, not requirements as laid out in the guidance, this information will be beneficial to facilitate FDA's prioritization efforts.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby
TOPICS: Monkeypox EUA submissions, FDA recommendations, EUA prioritization
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: What should be done if a developer's question sent via email to FDA is not answered during the town hall?
CLARIFIED ANSWER: Developers should look for a written response if their emailed question is not addressed during the town hall. If no response is received within a few days, they should follow up by contacting FDA through the appropriate email mailbox.
VERBATIM QUESTION: What should be done if a developer's question sent via email to FDA is not answered during the town hall?
VERBATIM ANSWER: As always, please note we do receive some emailed questions that are too detailed or test case specific that we will not address during today's town hall. For those questions, we will try to send a response in writing within a few days. If you have submitted a question and do not hear it addressed today, please look for a written response. If you do not receive a response within a few days, please feel free to reach back out to the appropriate mailbox, either the MPXDx@fda.hhs.gov mailbox or the COVID19DX@fda.hhs.gov mailbox for an update.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Commander Kimberly Piermatteo (FDA)
TOPICS: follow up for responses, email communication with FDA
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: What type of information is recommended to include in an intent to submit an EUA request for a diagnostic test?
CLARIFIED ANSWER: FDA recommends including information such as the test technology, manufacturing capacity, throughput, available validation data, and the timeline for validation and EUA submission in the intent to submit an EUA request. These are recommendations, not requirements, aimed at aiding FDA's prioritization.
VERBATIM QUESTION: What type of information is recommended to include in an intent to submit an EUA request for a diagnostic test?
VERBATIM ANSWER: As discussed in the monkeypox test policy guidance, FDA generally recommends including certain preliminary information in the test developer's email to FDA to indicate their intent to submit an EUA request for a monkeypox diagnostic test. So that information includes the description of the test technology, manufacturing capacity, test throughput, any available validation data, and the expected timeline for development validation and submission of an EUA request. While these are recommendations, not requirements as laid out in the guidance, this information will be beneficial to facilitate FDA's prioritization efforts.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Commander Kimberly Piermatteo (FDA)
TOPICS: EUA submission, diagnostic test protocols, FDA recommendations
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: What is the difference between FDA's recommendations and requirements for EUA submissions?
CLARIFIED ANSWER: FDA distinguishes between recommendations and requirements for EUA submissions. Recommendations include providing preliminary information such as test description, manufacturing capacity, validation data, and timeline, which are voluntary but help facilitate prioritization. Requirements are not explicitly stated in this segment.
VERBATIM QUESTION: What is the difference between FDA's recommendations and requirements for EUA submissions?
VERBATIM ANSWER: So as discussed in the monkeypox test policy guidance, FDA generally recommends including certain preliminary information in the test developer's email to FDA to indicate their intent to submit an EUA request for a monkeypox diagnostic test. So that information includes the description of the test technology, manufacturing capacity, test throughput, any available validation data, and the expected timeline for development validation and submission of an EUA request. While these are recommendations, not requirements as laid out in the guidance, this information will be beneficial to facilitate FDA's prioritization efforts.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Commander Kimberly Piermatteo (FDA)
TOPICS: FDA recommendations, EUA requirements, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: How does including preliminary information in an email to FDA help with prioritization of EUA requests?
CLARIFIED ANSWER: Providing preliminary information such as test technology description, manufacturing capacity, throughput, validation data, and development timeline helps FDA prioritize EUA requests effectively.
VERBATIM QUESTION: How does including preliminary information in an email to FDA help with prioritization of EUA requests?
VERBATIM ANSWER: FDA generally recommends including certain preliminary information in the test developer's email to FDA to indicate their intent to submit an EUA request for a monkeypox diagnostic test. So that information includes the description of the test technology, manufacturing capacity, test throughput, any available validation data, and the expected timeline for development validation and submission of an EUA request. While these are recommendations, not requirements as laid out in the guidance, this information will be beneficial to facilitate FDA's prioritization efforts.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Commander Kimberly Piermatteo (FDA)
TOPICS: EUA prioritization, Preliminary information, FDA recommendations
REVIEW FLAG: False


#### 3. Consideration of Over-the-Counter Multianalyte Diagnostic Tests

QA Block 3-1
CLARIFIED QUESTION: Is FDA considering multiplex antigen tests that can detect a combination of viruses, such as SARS-CoV-2 and influenza, for use in an over-the-counter setting for symptomatic users only?
CLARIFIED ANSWER: The FDA has authorized some multianalyte tests for lab and point-of-care use, including those using home-collected specimens, but has not yet authorized over-the-counter multianalyte tests. FDA is considering such tests and recommends pre-submission and a traditional marketing pathway.
VERBATIM QUESTION: Is FDA considering multiplex antigen tests that can detect a combination of viruses, such as SARS-CoV-2 and influenza, for use in an over-the-counter setting for symptomatic users only?
VERBATIM ANSWER: Thanks, Kim. And sorry for that typo in the question. That tripped you up there. Definitely meant to be SARS-CoV-2 and influenza. And so we have authorized a few antigen multianalyte diagnostic tests intended for use at laboratory and point of care sites as well as several molecular multianalyte diagnostic tests intended for use at laboratory and point of care sites for use with home collected specimens. We have not yet authorized any multianalyte over-the-counter tests. However, we do have recommendations in the EUA templates and have discussed on previous town halls that we are considering over-the-counter multianalyte tests. Following issuance of the updated guidance yesterday, we recommend that you consider a pre-submission and traditional marketing pathway for this type of test.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: multiplex antigen tests, over-the-counter diagnostics, FDA authorization
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: What does the FDA recommend for developers preparing to submit over-the-counter multianalyte antigen tests for authorization?
CLARIFIED ANSWER: The FDA recommends considering a pre-submission and traditional marketing pathway for over-the-counter multianalyte antigen tests after the updated guidance issued.
VERBATIM QUESTION: What does the FDA recommend for developers preparing to submit over-the-counter multianalyte antigen tests for authorization?
VERBATIM ANSWER: Following issuance of the updated guidance yesterday, we recommend that you consider a pre-submission and traditional marketing pathway for this type of test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: over-the-counter tests, authorization pathway, FDA guidance
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: Are there specific guidance updates that developers should review before pursuing a pre-submission for over-the-counter multianalyte tests?
CLARIFIED ANSWER: FDA recommends reviewing the updated guidance issued yesterday and considering a pre-submission and traditional marketing pathway for over-the-counter multianalyte tests.
VERBATIM QUESTION: Are there specific guidance updates that developers should review before pursuing a pre-submission for over-the-counter multianalyte tests?
VERBATIM ANSWER: Following issuance of the updated guidance yesterday, we recommend that you consider a pre-submission and traditional marketing pathway for this type of test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Over-the-counter multianalyte tests, Guidance updates, Pre-submission recommendations
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: Does the FDA provide templates or specific recommendations for multianalyte diagnostic tests that integrate home-collected specimens?
CLARIFIED ANSWER: The FDA has authorized multianalyte tests for use with home-collected specimens in lab and point-of-care settings and provides relevant recommendations in EUA templates. They suggest pursuing a pre-submission and traditional marketing pathway for such tests.
VERBATIM QUESTION: Does the FDA provide templates or specific recommendations for multianalyte diagnostic tests that integrate home-collected specimens?
VERBATIM ANSWER: We have authorized a few antigen multianalyte diagnostic tests intended for use at laboratory and point of care sites as well as several molecular multianalyte diagnostic tests intended for use at laboratory and point of care sites for use with home collected specimens. We have not yet authorized any multianalyte over-the-counter tests. However, we do have recommendations in the EUA templates and have discussed on previous town halls that we are considering over-the-counter multianalyte tests. Following issuance of the updated guidance yesterday, we recommend that you consider a pre-submission and traditional marketing pathway for this type of test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Multianalyte diagnostic tests, EUA templates, Home-collected specimens
REVIEW FLAG: False


#### 4. FDA Recommendations for COVID-19 Rapid Test Validation

QA Block 4-1
CLARIFIED QUESTION: To support 510(k) for COVID-19 rapid tests, is FDA requiring serial testing as part of the clinical performance study for symptomatic individuals?
CLARIFIED ANSWER: FDA recommends submitting a pre-submission to discuss validation strategies for a 510(k). Serial testing is now recommended for all rapid antigen tests, including for symptomatic individuals, and updated templates will reflect this.
VERBATIM QUESTION: To support 510(k) for COVID-19 rapid tests, is FDA requiring serial testing as part of the clinical performance study for symptomatic individuals?
VERBATIM ANSWER: So we do continue to recommend submitting a pre-submission to discuss your proposed clinical validation strategies if you intend to pursue a 510k. We have not yet granted a de novo for a COVID-19 rapid antigen test, so we cannot say with certainty exactly what will be required for a 510k. As is discussed in our safety communication issued in August, we are now recommending serial testing for all rapid antigen tests, including for symptomatic individuals. And we will be updating our recommendations in the template to reflect this.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: COVID-19 rapid test 510(k) requirements, serial testing, symptomatic individuals
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: What are the recommended clinical validation strategies for pursuing a 510k for COVID-19 rapid antigen tests?
CLARIFIED ANSWER: FDA recommends submitting a pre-submission to discuss your proposed clinical validation strategies. They currently recommend serial testing for all rapid antigen tests, including for symptomatic individuals, and will update their templates with further recommendations.
VERBATIM QUESTION: What are the recommended clinical validation strategies for pursuing a 510k for COVID-19 rapid antigen tests?
VERBATIM ANSWER: So we do continue to recommend submitting a pre-submission to discuss your proposed clinical validation strategies if you intend to pursue a 510k. We have not yet granted a de novo for a COVID-19 rapid antigen test, so we cannot say with certainty exactly what will be required for a 510k. As is discussed in our safety communication issued in August, we are now recommending serial testing for all rapid antigen tests, including for symptomatic individuals. And we will be updating our recommendations in the template to reflect this.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 510k clinical validation strategies, COVID-19 rapid antigen tests, serial testing requirements
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Does the FDA's recommendation for serial testing apply to all rapid antigen tests or only specific types?
CLARIFIED ANSWER: The FDA recommends serial testing for all rapid antigen tests, including tests intended for symptomatic individuals.
VERBATIM QUESTION: Does the FDA's recommendation for serial testing apply to all rapid antigen tests or only specific types?
VERBATIM ANSWER: As is discussed in our safety communication issued in August, we are now recommending serial testing for all rapid antigen tests, including for symptomatic individuals. And we will be updating our recommendations in the template to reflect this.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serial testing, rapid antigen tests, FDA guidelines
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: When will the FDA update the templates to reflect the new recommendations regarding serial testing?
CLARIFIED ANSWER: FDA plans to update the templates to reflect the new recommendations on serial testing, which includes all rapid antigen tests and symptomatic individuals.
VERBATIM QUESTION: When will the FDA update the templates to reflect the new recommendations regarding serial testing?
VERBATIM ANSWER: As is discussed in our safety communication issued in August, we are now recommending serial testing for all rapid antigen tests, including for symptomatic individuals. And we will be updating our recommendations in the template to reflect this.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Serial testing, Template updates, COVID-19 rapid tests
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: What is the de novo pathway status for COVID-19 rapid antigen tests and why has one not yet been granted?
CLARIFIED ANSWER: The FDA has not yet granted a de novo for COVID-19 rapid antigen tests, so it is uncertain what exactly will be required for a 510k.
VERBATIM QUESTION: What is the de novo pathway status for COVID-19 rapid antigen tests and why has one not yet been granted?
VERBATIM ANSWER: We have not yet granted a de novo for a COVID-19 rapid antigen test, so we cannot say with certainty exactly what will be required for a 510k.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: de novo pathway, COVID-19 rapid antigen tests, 510k requirements
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: What details are included in the August safety communication mentioned regarding serial testing recommendations?
CLARIFIED ANSWER: The FDA's August safety communication recommends serial testing for all rapid antigen tests, including those for symptomatic individuals, and indicates forthcoming updates to FDA templates.
VERBATIM QUESTION: What details are included in the August safety communication mentioned regarding serial testing recommendations?
VERBATIM ANSWER: As is discussed in our safety communication issued in August, we are now recommending serial testing for all rapid antigen tests, including for symptomatic individuals. And we will be updating our recommendations in the template to reflect this.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: August safety communication, Serial testing recommendations, Rapid antigen tests
REVIEW FLAG: False


#### 5. FDA Guidance on Serial Testing and Validation Requirements

QA Block 5-2
CLARIFIED QUESTION: Will the FDA require additional clinical study results under a 510k for serial testing recommendations with at-home COVID-19 antigen tests?
CLARIFIED ANSWER: The FDA is not likely to request additional studies for serial testing under EUA due to available NIH data but recommends pre-submission discussions for pursuing 510k applications.
VERBATIM QUESTION: Will the FDA require additional clinical study results under a 510k for serial testing recommendations with at-home COVID-19 antigen tests?
VERBATIM ANSWER: So we have discussed a bit on previous town halls that FDA continues to work to reflect the need for serial testing in antigen test authorizations. The results of the NIH-supported UMass study have been published. And FDA plans to use this data in support of serial testing claims. One of the goals of the study was to provide broadly applicable data to avoid the need for individual developers to perform large and expensive tests-- or expensive studies, rather. And so at this time, the FDA is not likely to request additional studies to support serial testing under EUA. And as I noted previously, we do continue to recommend submitting a pre-submission to discuss your proposed clinical validation strategies if you intend to pursue a 510k.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: At-home COVID-19 antigen tests, Serial testing requirements, 510k applications
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: Is the right to reference the NIH-supported UMass study sufficient for serial testing claims without conducting additional clinical studies?
CLARIFIED ANSWER: The FDA finds the NIH-supported UMass study sufficient to support serial testing claims and does not expect to request additional clinical studies under EUA, though they recommend pre-submissions for 510k validation strategies.
VERBATIM QUESTION: Is the right to reference the NIH-supported UMass study sufficient for serial testing claims without conducting additional clinical studies?
VERBATIM ANSWER: The results of the NIH-supported UMass study have been published. And FDA plans to use this data in support of serial testing claims. One of the goals of the study was to provide broadly applicable data to avoid the need for individual developers to perform large and expensive tests-- or expensive studies, rather. And so at this time, the FDA is not likely to request additional studies to support serial testing under EUA. And as I noted previously, we do continue to recommend submitting a pre-submission to discuss your proposed clinical validation strategies if you intend to pursue a 510k.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Serial testing claims, NIH-supported UMass study, EUA and 510k submissions
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: How will the FDA integrate the NIH-Utsupported UMass study data into the authorization of at-home COVID-19 antigen tests?
CLARIFIED ANSWER: The FDA will use data from the NIH-supported UMass study to support serial testing claims for at-home antigen tests. This avoids the need for individual developers to conduct large studies, though the FDA recommends a pre-submission for 510k clinical validation discussions.
VERBATIM QUESTION: How will the FDA integrate the NIH-Utsupported UMass study data into the authorization of at-home COVID-19 antigen tests?
VERBATIM ANSWER: FDA continues to work to reflect the need for serial testing in antigen test authorizations. The results of the NIH-supported UMass study have been published. And FDA plans to use this data in support of serial testing claims. One of the goals of the study was to provide broadly applicable data to avoid the need for individual developers to perform large and expensive tests-- or expensive studies, rather. And so at this time, the FDA is not likely to request additional studies to support serial testing under EUA. And as I noted previously, we do continue to recommend submitting a pre-submission to discuss your proposed clinical validation strategies if you intend to pursue a 510k.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: NIH-supported UMass study, Serial testing authorization, At-home COVID-19 antigen tests
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: Does the FDA recommend a pre-submission process to discuss clinical validation strategies even if developers are utilizing the NIH-supported UMass study data?
CLARIFIED ANSWER: FDA recommends that developers submit a pre-submission to discuss proposed clinical validation strategies if they intend to pursue a 510k, even if utilizing NIH-supported UMass study data.
VERBATIM QUESTION: Does the FDA recommend a pre-submission process to discuss clinical validation strategies even if developers are utilizing the NIH-supported UMass study data?
VERBATIM ANSWER: And as I noted previously, we do continue to recommend submitting a pre-submission to discuss your proposed clinical validation strategies if you intend to pursue a 510k.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Pre-submission process, Clinical validation strategies, 510k submission
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: Can developers entirely bypass conducting clinical studies if their labeling aligns with the NIH-supported UMass study data and FDA guidance?
CLARIFIED ANSWER: Developers may not need to conduct additional clinical studies for serial testing under EUA if their labeling aligns with the NIH-supported UMass study data. For pursuing a 510k, FDA recommends pre-submission to discuss clinical validation strategies.
VERBATIM QUESTION: Can developers entirely bypass conducting clinical studies if their labeling aligns with the NIH-supported UMass study data and FDA guidance?
VERBATIM ANSWER: The results of the NIH-supported UMass study have been published. And FDA plans to use this data in support of serial testing claims. One of the goals of the study was to provide broadly applicable data to avoid the need for individual developers to perform large and expensive tests-- or expensive studies, rather. And so at this time, the FDA is not likely to request additional studies to support serial testing under EUA. And as I noted previously, we do continue to recommend submitting a pre-submission to discuss your proposed clinical validation strategies if you intend to pursue a 510k.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Clinical studies waiver, NIH-supported UMass study, FDA EUA process
REVIEW FLAG: False


#### 6. Guidance for At-Home COVID Test Study Procedures

QA Block 6-1
CLARIFIED QUESTION: To support an at-home testing claim, in a clinical study where the comparator is not being used as the standard of care, does FDA recommend that clinical study subjects swab themselves and perform the test before the comparator swab is taken, in order to not train or mislead the lay tester?
CLARIFIED ANSWER: The FDA recommends study participants swab themselves and perform the at-home test first to minimize bias before the comparator swab is taken.
VERBATIM QUESTION: To support an at-home testing claim, in a clinical study where the comparator is not being used as the standard of care, does FDA recommend that clinical study subjects swab themselves and perform the test before the comparator swab is taken, in order to not train or mislead the lay tester?
VERBATIM ANSWER: Yes. FDA continues to recommend that study participants swab themselves and perform self-testing before the comparator swab is collected in order to minimize potential bias.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: at-home testing, clinical study protocol, minimizing bias
REVIEW FLAG: False


#### 7. Clarifications on FDA Pre-EUA Test Review Process

QA Block 7-1
CLARIFIED QUESTION: Can you clarify if the pre-EUAs that have already been submitted and are under review prior to this announcement will still remain in the queue?
CLARIFIED ANSWER: Pre-EUAs submitted before the update will not stay in the queue unless they meet new priority criteria. Developers should consider converting pre-EUAs to a pre-submission for traditional authorization.
VERBATIM QUESTION: Can you clarify if the pre-EUAs that have already been submitted and are under review prior to this announcement will still remain in the queue?
VERBATIM ANSWER: So Toby can back me up on this. But EUAs that are in the queue have all the data relevant to the submission. And they will remain in the queue through the completion of the review and the decision made on that. Pre-EUAs are designed to provide feedback on test development and are not designed for a submission for authorization. So those with pending pre-EUAs, if they wish to make a submission to the FDA, it would be through the traditional route unless it meets some of the unusual conditions for continued EUA review. That can be assessed through a pre-EUA to determine whether we would at this point accept an EUA submission. So if a test developer wants to market a test that isn't one of the unusual categories that we would still review, I would recommend that you convert that pre-EUA, those questions, into a Q-sub or pre-sub submission to the FDA to find out what the expectations are for a full authorization submission.
SPEAKER QUESTION: Kal Mansoor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-EUA policy, Queue retention, Submission guidance
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: Should test developers with pending pre-EUAs convert those into a Q-sub or pre-sub submission to the FDA if the test does not meet the conditions for continued EUA review?
CLARIFIED ANSWER: FDA recommends that test developers with pending pre-EUAs convert them into a Q-sub or pre-sub submission if their test does not meet the conditions for continued EUA review, in order to clarify expectations for full authorization.
VERBATIM QUESTION: Should test developers with pending pre-EUAs convert those into a Q-sub or pre-sub submission to the FDA if the test does not meet the conditions for continued EUA review?
VERBATIM ANSWER: Pre-EUAs are designed to provide feedback on test development and are not designed for a submission for authorization. So those with pending pre-EUAs, if they wish to make a submission to the FDA, it would be through the traditional route unless it meets some of the unusual conditions for continued EUA review. That can be assessed through a pre-EUA to determine whether we would at this point accept an EUA submission. So if a test developer wants to market a test that isn't one of the unusual categories that we would still review, I would recommend that you convert that pre-EUA, those questions, into a Q-sub or pre-sub submission to the FDA to find out what the expectations are for a full authorization submission.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA to Q-Sub conversion, Pre-EUA submissions, FDA guidance
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: Should we reach out to our pre-EUA reviewer to see if the review is still ongoing, or should we just wait?
CLARIFIED ANSWER: Yes, developers can reach out to their pre-EUA reviewer to inquire about the status of their review, but response times may vary depending on the queue.
VERBATIM QUESTION: Should we reach out to our pre-EUA reviewer to see if the review is still ongoing, or should we just wait?
VERBATIM ANSWER: No, you can reach out. And you can ask if your test would qualify. But if there's a large queue, I don't know how quickly they can do that review. But they'll get back to you.
SPEAKER QUESTION: Kal Mansoor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA review process, inquiry availability, review timelines
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: What differentiates a pre-EUA from an actual EUA submission in terms of regulatory purpose and use during the COVID-19 pandemic?
CLARIFIED ANSWER: Pre-EUAs provide feedback on test development and are not intended for authorization submission, whereas EUAs are for full data review and authorization decisions. Pre-EUAs may guide if an EUA submission is appropriate under specific conditions.
VERBATIM QUESTION: What differentiates a pre-EUA from an actual EUA submission in terms of regulatory purpose and use during the COVID-19 pandemic?
VERBATIM ANSWER: Pre-EUAs are designed to provide feedback on test development and are not designed for a submission for authorization. So those with pending pre-EUAs, if they wish to make a submission to the FDA, it would be through the traditional route unless it meets some of the unusual conditions for continued EUA review. That can be assessed through a pre-EUA to determine whether we would at this point accept an EUA submission.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA purpose, EUA regulatory process, COVID-19 test review
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: Under what conditions would a pre-EUA submission qualify for continued EUA review given the new priorities?
CLARIFIED ANSWER: A pre-EUA submission qualifies for continued EUA review only if it meets specific unusual conditions under the new priorities. Developers should assess this via a pre-EUA or convert to a Q-sub or pre-submission for guidance on full authorization.
VERBATIM QUESTION: Under what conditions would a pre-EUA submission qualify for continued EUA review given the new priorities?
VERBATIM ANSWER: Pre-EUAs are designed to provide feedback on test development and are not designed for a submission for authorization. So those with pending pre-EUAs, if they wish to make a submission to the FDA, it would be through the traditional route unless it meets some of the unusual conditions for continued EUA review. That can be assessed through a pre-EUA to determine whether we would at this point accept an EUA submission. So if a test developer wants to market a test that isn't one of the unusual categories that we would still review, I would recommend that you convert that pre-EUA, those questions, into a Q-sub or pre-sub submission to the FDA to find out what the expectations are for a full authorization submission.
SPEAKER QUESTION: Kal Mansoor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA qualification, EUA review priorities, submission process
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: If a pre-EUA does not meet the criteria for continued review, what are the specific steps to convert it to a Q-sub or pre-submission?
CLARIFIED ANSWER: To convert a pre-EUA to a Q-sub or pre-sub if it does not meet criteria for continued review, the FDA recommends developers submit their questions through the Q-submission or pre-submission route to clarify expectations for full authorization.
VERBATIM QUESTION: If a pre-EUA does not meet the criteria for continued review, what are the specific steps to convert it to a Q-sub or pre-submission?
VERBATIM ANSWER: So those with pending pre-EUAs, if they wish to make a submission to the FDA, it would be through the traditional route unless it meets some of the unusual conditions for continued EUA review. That can be assessed through a pre-EUA to determine whether we would at this point accept an EUA submission. So if a test developer wants to market a test that isn't one of the unusual categories that we would still review, I would recommend that you convert that pre-EUA, those questions, into a Q-sub or pre-sub submission to the FDA to find out what the expectations are for a full authorization submission.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-EUA conversion process, Q-submission, FDA submission guidance
REVIEW FLAG: False

QA Block 7-7
CLARIFIED QUESTION: How will the FDA communicate to sponsors whether their submission is being reviewed or closed without feedback, based on new priorities?
CLARIFIED ANSWER: The FDA will notify sponsors if their submission is either closed without feedback or under review, depending on test type and priority.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We will be making our way through the submissions that are in the queue. And we will be sending responses to the sponsors. The response may be that this is closed and we're not providing feedback at this time. Or it may be that we are continuing to review, depending on the type of test and where it falls in our priorities.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA communication, Submission review process, EUA priorities
REVIEW FLAG: False

QA Block 7-8
CLARIFIED QUESTION: What criteria determine whether a COVID-19 diagnostic test submission remains in the queue or is deprioritized?
CLARIFIED ANSWER: Tests with all necessary data and pending EUAs will remain in the queue. Pre-EUAs are designed for feedback, not authorization. If a test aligns with new EUA review priorities, it may continue; otherwise, a marketing submission is recommended.
VERBATIM QUESTION: What criteria determine whether a COVID-19 diagnostic test submission remains in the queue or is deprioritized?
VERBATIM ANSWER: EUAs that are in the queue have all the data relevant to the submission. And they will remain in the queue through the completion of the review and the decision made on that. Pre-EUAs are designed to provide feedback on test development and are not designed for a submission for authorization. So those with pending pre-EUAs, if they wish to make a submission to the FDA, it would be through the traditional route unless it meets some of the unusual conditions for continued EUA review. That can be assessed through a pre-EUA to determine whether we would at this point accept an EUA submission. If the pre-EUA is for a test that would meet the new priorities for EUA review, then we are likely to continue to review the pre-EUA. If it is not of a type that we would intend to prioritize, then your best bet at that point is to proceed with a pre-submission and look towards that marketing submission.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA criteria, Test prioritization, FDA submission process
REVIEW FLAG: False


#### 8. Defining Successful EUA Requests and Experienced Developers

QA Block 8-2
CLARIFIED QUESTION: Does a successful EUA request include the actual EUA approval and/or pre-EUA interactions?
CLARIFIED ANSWER: A successful EUA request refers to being issued an EUA authorization following the submission of an EUA request and does not include any pre-EUA interactions.
VERBATIM QUESTION: Does a successful EUA request include the actual EUA approval and/or pre-EUA interactions?
VERBATIM ANSWER: It's a similar language in both guidances I believe at this point. So a successful EUA request would be having been issued an EUA following submission of an EUA request. Correct. EUA authorization. Yes. That's correct.
SPEAKER QUESTION: Ashanti Brown
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA request definition, EUA authorization process
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: Can you elaborate on what a similar experience would be for an experienced developer?
CLARIFIED ANSWER: FDA considers similar experience to be a positive decision on submissions to FDA for in vitro diagnostic tests, such as EUA authorizations, traditional 510k clearances, de novo grants, or PMA approvals.
VERBATIM QUESTION: Can you elaborate on what a similar experience would be for an experienced developer?
VERBATIM ANSWER: Excuse me. So we would be happy to answer a specific question if you want to reach out about a specific developer. But generally, that's going to be a developer that's had a positive decision on a submission to FDA, whether that's an EUA or a premarket submission under a traditional 510k. Yeah. So for a test, for an IVD test, not for other products, but for IVD tests for a 510k clearance, or a de novo granted, or a PMA approval.
SPEAKER QUESTION: Ashanti Brown
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: experienced developer qualifications, EUA criteria, FDA submission process
REVIEW FLAG: False


#### 9. FDA Acceptance of International Data for Monkeypox Testing

QA Block 9-2
CLARIFIED QUESTION: Does the FDA accept clinical study data from outside of the US for high throughput devices for high complexity labs for monkeypox?
CLARIFIED ANSWER: FDA may accept clinical study data from outside the US for certain devices, but a key challenge is the unavailability of the CDC NVO orthopox comparator test for such studies. FDA suggests submitting a pre-EUA for detailed guidance.
VERBATIM QUESTION: Does the FDA accept clinical study data from outside of the US for high throughput devices for high complexity labs for monkeypox?
VERBATIM ANSWER: That's possible. The comparator tests that the FDA recognizes at the moment is the CDC NVO orthopox test that is FDA cleared. So I don't believe that that's available for this kind of study. So that would be the challenge with that. But I think this is a very specific question. And you can come in with a pre-EUA for that question.
SPEAKER QUESTION: Niya Su
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Clinical study data, High throughput devices, Monkeypox testing
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: What comparator tests does the FDA recommend for clinical studies on monkeypox diagnostics?
CLARIFIED ANSWER: The FDA currently recognizes the CDC NVO orthopox test as the comparator test for monkeypox diagnostics.
VERBATIM QUESTION: What comparator tests does the FDA recommend for clinical studies on monkeypox diagnostics?
VERBATIM ANSWER: The comparator tests that the FDA recognizes at the moment is the CDC NVO orthopox test that is FDA cleared.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: monkeypox diagnostics, comparator tests, FDA recommendations
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: Is the CDC NVO orthopox test available outside of the US for use in comparative studies?
CLARIFIED ANSWER: The CDC NVO orthopox test is likely not available for comparative studies outside the US, but the FDA recommends submitting a pre-EUA to address specific questions.
VERBATIM QUESTION: Is the CDC NVO orthopox test available outside of the US for use in comparative studies?
VERBATIM ANSWER: I don't believe that that's available for this kind of study. So that would be the challenge with that. But I think this is a very specific question. And you can come in with a pre-EUA for that question.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CDC NVO orthopox test availability, Comparative studies, Pre-EUA recommendation
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: What steps are needed to submit a pre-EUA related to monkeypox diagnostic tests?
CLARIFIED ANSWER: FDA advises submitting a pre-EUA for specific questions regarding monkeypox diagnostic tests.
VERBATIM QUESTION: What steps are needed to submit a pre-EUA related to monkeypox diagnostic tests?
VERBATIM ANSWER: I think this is a very specific question. And you can come in with a pre-EUA for that question.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: monkeypox diagnostic tests, pre-EUA submission
REVIEW FLAG: False


#### 10. COVID-19 Test Submissions and Sample Recommendations

QA Block 10-1
CLARIFIED QUESTION: For the EUA of antigen COVID-19 at-home test kits, how many positive, negative, and asymptomatic samples are recommended for the 510(k) submission pathway instead of the EUA?
CLARIFIED ANSWER: The determination of sample recommendations for the 510(k) submission pathway depends on details of the test; FDA recommends using the Q-Sub or Pre-Sub submission process to obtain guidance from their COVID team.
VERBATIM QUESTION: For the EUA of antigen COVID-19 at-home test kits, how many positive, negative, and asymptomatic samples are recommended for the 510(k) submission pathway instead of the EUA?
VERBATIM ANSWER: So a lot of this depends on all the aspects of your test and what you're seeking for the test. It's best handled through a Q-Sub or Pre-Sub submission or normal Q-Sub Pre-Submission process that will then be directed to our COVID team to help you. We have prepared recommendations for antigen tests. And that team can provide those to you under that process.
SPEAKER QUESTION: Mary Ann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 510(k) submission pathway, antigen tests, sample recommendations
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: What is the process for obtaining FDA recommendations specific to 510(k) submissions for antigen COVID-19 at-home test kits?
CLARIFIED ANSWER: FDA recommends using the Q-Sub or Pre-Sub process, which will direct the inquiry to their COVID team. This team can provide specific recommendations for antigen tests, including for 510(k) submissions.
VERBATIM QUESTION: What is the process for obtaining FDA recommendations specific to 510(k) submissions for antigen COVID-19 at-home test kits?
VERBATIM ANSWER: It's best handled through a Q-Sub or Pre-Sub submission or normal Q-Sub Pre-Submission process that will then be directed to our COVID team to help you. We have prepared recommendations for antigen tests. And that team can provide those to you under that process.
SPEAKER QUESTION: Mary Ann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 510(k) submission process, antigen test recommendations, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: Does the FDA provide guidance for the number of positive, negative, and asymptomatic samples required for the 510(k) submission pathway?
CLARIFIED ANSWER: FDA recommends using the Q-Sub or Pre-Sub process for specific guidance on sample requirements, as it varies based on test specifics. They have prepared recommendations for antigen tests accessible through this process.
VERBATIM QUESTION: Does the FDA provide guidance for the number of positive, negative, and asymptomatic samples required for the 510(k) submission pathway?
VERBATIM ANSWER: So a lot of this depends on all the aspects of your test and what you're seeking for the test. It's best handled through a Q-Sub or Pre-Sub submission or normal Q-Sub Pre-Submission process that will then be directed to our COVID team to help you. We have prepared recommendations for antigen tests. And that team can provide those to you under that process.
SPEAKER QUESTION: Mary Ann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 510(k) submission pathway, sample requirements, COVID-19 antigen tests
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: How does the Q-Sub or Pre-Sub process facilitate access to guidelines for COVID-19 antigen tests?
CLARIFIED ANSWER: The Q-Sub or Pre-Sub process facilitates access to FDA's prepared recommendations for antigen tests by directing submissions to the COVID team, which provides guidance under that process.
VERBATIM QUESTION: How does the Q-Sub or Pre-Sub process facilitate access to guidelines for COVID-19 antigen tests?
VERBATIM ANSWER: It's best handled through a Q-Sub or Pre-Sub submission or normal Q-Sub Pre-Submission process that will then be directed to our COVID team to help you. We have prepared recommendations for antigen tests. And that team can provide those to you under that process.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Q-Sub and Pre-Sub process, COVID-19 antigen test guidelines, FDA recommendations
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: Are the prepared recommendations for antigen tests specific to at-home test kits or applicable to all antigen tests?
CLARIFIED ANSWER: The FDA has prepared recommendations for antigen tests, which can be provided through their submission process. These recommendations are not specified as being exclusive to at-home test kits.
VERBATIM QUESTION: Are the prepared recommendations for antigen tests specific to at-home test kits or applicable to all antigen tests?
VERBATIM ANSWER: We have prepared recommendations for antigen tests. And that team can provide those to you under that process.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test recommendations, submission process
REVIEW FLAG: False


#### 11. Defining New Technologies and Unmet Needs in COVID Policies

QA Block 11-1
CLARIFIED QUESTION: Can you elaborate on and provide more examples of the meaning of new technologies and fulfilling an unmet need in the context of the COVID-19 re-prioritization policy?
CLARIFIED ANSWER: FDA considers new technologies as anything valuable to the pandemic or the ongoing COVID emergency that isn't a repeat or me too product. For instance, breath tests are a novel technology where only one authorization exists, and the FDA is accepting additional submissions for such examples. Technologies can be reviewed through a pre-EUA submission to determine eligibility.
VERBATIM QUESTION: Can you elaborate on and provide more examples of the meaning of new technologies and fulfilling an unmet need in the context of the COVID-19 re-prioritization policy?
VERBATIM ANSWER: Yeah. Yeah. I mean, it's anything that would be valuable to the pandemic or to the ongoing COVID emergency now and isn't a me too product. For several categories of tests, we have multiple examples of them. One is new technology where we only have one authorization that is open for EUA submissions is the breath test. We authorized one breath test. And we're willing to accept additional breath tests. At some point, we may have more than enough breath tests. And the policy may be updated again. But that's a concrete example of a new technology where we only have one authorization. So where we have plenty of tests already authorized, and an additional test would be a me too test, that's what we're steering away from now. You can come in for a pre-EUA submission to ask if your technology would be likely to qualify under that novel technology exception.
SPEAKER QUESTION: KB
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: new technologies, unmet need, COVID-19 re-prioritization policy
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: In the context of COVID-19 diagnostics, can a company submit a pre-EUA submission to determine if their technology would qualify as a novel technology?
CLARIFIED ANSWER: FDA allows companies to submit a pre-EUA submission to determine if their technology qualifies as a novel technology.
VERBATIM QUESTION: In the context of COVID-19 diagnostics, can a company submit a pre-EUA submission to determine if their technology would qualify as a novel technology?
VERBATIM ANSWER: You can come in for a pre-EUA submission to ask if your technology would be likely to qualify under that novel technology exception.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA submissions, novel technology, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: What constitutes a 'me too' product in the context of COVID-19 re-prioritization policy?
CLARIFIED ANSWER: A 'me too' product refers to tests for which many similar tests are already authorized. FDA is currently avoiding authorizing additional tests in categories where there is sufficient availability unless the test represents a novel technology.
VERBATIM QUESTION: What constitutes a 'me too' product in the context of COVID-19 re-prioritization policy?
VERBATIM ANSWER: Yeah. Yeah. I mean, it's anything that would be valuable to the pandemic or to the ongoing COVID emergency now and isn't a me too product. For several categories of tests, we have multiple examples of them. One is new technology where we only have one authorization that is open for EUA submissions is the breath test. We authorized one breath test. And we're willing to accept additional breath tests. At some point, we may have more than enough breath tests. And the policy may be updated again. But that's a concrete example of a new technology where we only have one authorization. So where we have plenty of tests already authorized, and an additional test would be a me too test, that's what we're steering away from now. You can come in for a pre-EUA submission to ask if your technology would be likely to qualify under that novel technology exception.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 test prioritization policy, Definition of 'me too' product, Emergency Use Authorization
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: Is the FDA currently open to accepting additional submissions for breath tests as a novel technology?
CLARIFIED ANSWER: The FDA is open to accepting additional submissions for breath tests as a novel technology. Currently, only one breath test is authorized. However, this policy may change if sufficient breath tests are authorized.
VERBATIM QUESTION: Is the FDA currently open to accepting additional submissions for breath tests as a novel technology?
VERBATIM ANSWER: One is new technology where we only have one authorization that is open for EUA submissions is the breath test. We authorized one breath test. And we're willing to accept additional breath tests. At some point, we may have more than enough breath tests. And the policy may be updated again.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Breath test authorizations, Novel COVID-19 test technologies
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: Will the FDA update the policy if the number of breath tests reaches a saturation point?
CLARIFIED ANSWER: The FDA may update its policy if the number of breath tests reaches a saturation point.
VERBATIM QUESTION: Will the FDA update the policy if the number of breath tests reaches a saturation point?
VERBATIM ANSWER: At some point, we may have more than enough breath tests. And the policy may be updated again.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: breath tests, policy update, COVID-19 diagnostics
REVIEW FLAG: False


#### 12. FDA Guidance Timeline for COVID-19 Test Developers

QA Block 12-1
CLARIFIED QUESTION: When can test developers expect to receive guidance regarding the studies referenced in the safety communication for at-home COVID-19 antigen tests and recommended labeling changes?
CLARIFIED ANSWER: The FDA is refining a process to reach out to all relevant EUA holders simultaneously with guidance and ensure all developers receive the information at the same time.
VERBATIM QUESTION: When can test developers expect to receive guidance regarding the studies referenced in the safety communication for at-home COVID-19 antigen tests and recommended labeling changes?
VERBATIM ANSWER: So we are continuing to work on that process because we will probably reach out to all relevant EUA holders at once with one process. And we're just refining that, so that it goes as smoothly as possible. Like Tim said, we do want to be able to cover all developers at the same time. So that's something we are addressing. And when we do reach out, we want to make sure that everyone has the information simultaneously. So that's where we are in the process right now.
SPEAKER QUESTION: Amanda
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA holder outreach, safety communication, COVID-19 antigen tests
REVIEW FLAG: False


#### 13. Clarifying Over-the-Counter COVID-19 Test Definitions

QA Block 13-1
CLARIFIED QUESTION: Does the Agency mean that over-the-counter multianalyte antigen tests are non-prescription, for example, for a test that's visually read, does not have a companion app, but is labeled for symptomatic users only?
CLARIFIED ANSWER: The FDA clarified that 'over-the-counter' is synonymous with 'non-prescription' and differs from prescription home use tests that require a prescription.
VERBATIM QUESTION: Does the Agency mean that over-the-counter multianalyte antigen tests are non-prescription, for example, for a test that's visually read, does not have a companion app, but is labeled for symptomatic users only?
VERBATIM ANSWER: Just to clarify some from a definition perspective, over-the-counter is, by definition, non- prescription. There is prescription home use, which is another sort of category of home use tests that do require a prescription. But over-the-counter is essentially synonymous with non-prescription.
SPEAKER QUESTION: Ling Koh
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: over-the-counter diagnostics, FDA definitions
REVIEW FLAG: False


#### 14. Evaluating User Comprehension in COVID Test Interpretation

QA Block 14-1
CLARIFIED QUESTION: Is interpretation of a low positive result required for usability comprehension studies involving COVID tests?
CLARIFIED ANSWER: FDA recommends that usability and comprehension evaluations include tests involving faint lines as they are important for assessing edge performance.
VERBATIM QUESTION: Is interpretation of a low positive result required for usability comprehension studies involving COVID tests?
VERBATIM ANSWER: Right. So user comprehension, of course, is reading the test. I think there's an element of both usability and comprehension. And I believe we do have some recommendations for what should be included in those studies. Of course, a bright line or a very dark easy to read line, perhaps, may have different usability or user comprehension than a faint line. So in general, we would want to have a comprehension of usability evaluated on the edges of the performance of the test. So certainly, faint lines would be helpful to evaluate those types of studies.
SPEAKER QUESTION: Tamasha Parsons
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: usability comprehension studies, low positive results, COVID tests
REVIEW FLAG: False

QA Block 14-2
CLARIFIED QUESTION: Are you referring to a COVID antigen test read by a lay user and differentiating between usability and user comprehension?
CLARIFIED ANSWER: User comprehension involves properly reading the test, and there are recommendations for assessing both usability and comprehension based on test performance edges like faint lines.
VERBATIM QUESTION: Are you referring to a COVID antigen test read by a lay user and differentiating between usability and user comprehension?
VERBATIM ANSWER: Right. So user comprehension, of course, is reading the test. I think there's an element of both usability and comprehension. And I believe we do have some recommendations for what should be included in those studies. Of course, a bright line or a very dark easy to read line, perhaps, may have different usability or user comprehension than a faint line. So in general, we would want to have a comprehension of usability evaluated on the edges of the performance of the test. So certainly, faint lines would be helpful to evaluate those types of studies.
SPEAKER QUESTION: Kris Roth (FDA)
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: COVID antigen test usability, User comprehension studies, Test performance evaluation
REVIEW FLAG: False

QA Block 14-3
CLARIFIED QUESTION: What are the FDA recommendations for designing usability and user comprehension studies for over-the-counter COVID antigen tests?
CLARIFIED ANSWER: FDA recommends that both usability and user comprehension be evaluated for over-the-counter COVID antigen tests. This includes assessing how well test results, such as faint lines, are interpreted at the performance edges.
VERBATIM QUESTION: What are the FDA recommendations for designing usability and user comprehension studies for over-the-counter COVID antigen tests?
VERBATIM ANSWER: Right. So user comprehension, of course, is reading the test. I think there's an element of both usability and comprehension. And I believe we do have some recommendations for what should be included in those studies. Of course, a bright line or a very dark easy to read line, perhaps, may have different usability or user comprehension than a faint line. So in general, we would want to have a comprehension of usability evaluated on the edges of the performance of the test. So certainly, faint lines would be helpful to evaluate those types of studies.
SPEAKER QUESTION: Tamasha Parsons
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: usability studies, user comprehension, COVID antigen tests
REVIEW FLAG: False

QA Block 14-4
CLARIFIED QUESTION: Should faint lines on COVID antigen tests specifically be included when evaluating user comprehension and usability?
CLARIFIED ANSWER: Faint lines on COVID antigen tests should be included in studies evaluating user comprehension and usability, especially at the edges of test performance.
VERBATIM QUESTION: Should faint lines on COVID antigen tests specifically be included when evaluating user comprehension and usability?
VERBATIM ANSWER: So user comprehension, of course, is reading the test. I think there's an element of both usability and comprehension. And I believe we do have some recommendations for what should be included in those studies. Of course, a bright line or a very dark easy to read line, perhaps, may have different usability or user comprehension than a faint line. So in general, we would want to have a comprehension of usability evaluated on the edges of the performance of the test. So certainly, faint lines would be helpful to evaluate those types of studies.
SPEAKER QUESTION: Tamasha Parsons
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: COVID antigen test usability, user comprehension, faint lines
REVIEW FLAG: False

QA Block 14-5
CLARIFIED QUESTION: Are there preferred ways to ensure over-the-counter COVID tests are easy to interpret by lay users, such as the brightness or darkness of test result lines?
CLARIFIED ANSWER: FDA recommends evaluating the usability and comprehension of over-the-counter COVID tests, especially considering factors like bright or dark easy-to-read lines versus faint lines in user comprehension studies.
VERBATIM QUESTION: Are there preferred ways to ensure over-the-counter COVID tests are easy to interpret by lay users, such as the brightness or darkness of test result lines?
VERBATIM ANSWER: Right. So user comprehension, of course, is reading the test. I think there's an element of both usability and comprehension. And I believe we do have some recommendations for what should be included in those studies. Of course, a bright line or a very dark easy to read line, perhaps, may have different usability or user comprehension than a faint line. So in general, we would want to have a comprehension of usability evaluated on the edges of the performance of the test. So certainly, faint lines would be helpful to evaluate those types of studies.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: usability and comprehension studies, result line visibility, OTC COVID tests
REVIEW FLAG: False


#### 15. Clarifications on New COVID Testing Guidance and Exceptions

QA Block 15-1
CLARIFIED QUESTION: Will the new EUA guidance apply to submissions already in the queue or only to new EUA submissions?
CLARIFIED ANSWER: The FDA will continue reviewing submissions already in the queue to determine their paths based on priorities and review status. Each submission will receive an individual decision, and no broad decisions will apply to all pending submissions.
VERBATIM QUESTION: Will the new EUA guidance apply to submissions already in the queue or only to new EUA submissions?
VERBATIM ANSWER: Yeah. So submissions that are currently pending will remain in the queue until we respond to the developer. So we will be making our way through those to determine whether or not they will proceed towards authorization or whether we will decline to issue. Those decisions will be made based on a combination of the priorities and where they are in the review. Something that's not going to meet the new priorities but was a couple of days away from being authorized, we're probably going to move forward with that. Something that was sort of sitting in the queue and does not meet the priorities, we would have to consider whether there are other factors that would apply there. So you sit tight, if you will. And you will hear an individual decision for each submission that's in-house. The information about those tests that are in queue was really intended to assure that there's not a blanket decision being made on all of the submissions that are in the queue.
SPEAKER QUESTION: Jennifer Stanford
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA guidance, Pending submissions, Review priorities
REVIEW FLAG: False

QA Block 15-2
CLARIFIED QUESTION: Does the new guidance apply to over-the-counter COVID home testing in addition to lab-developed tests?
CLARIFIED ANSWER: The new guidance does not apply to over-the-counter home tests or any testing involving home self-collection. It only applies to LDTs conducted in high complexity CLIA labs within certain states authorized under the State Authorization Policy.
VERBATIM QUESTION: Does the new guidance apply to over-the-counter COVID home testing in addition to lab-developed tests?
VERBATIM ANSWER: I think you may have misread that. I think the language that you're referring to, that it does not apply to home tests, was specifically on the slide about the State Authorization Policy. So that is only for that policy where a specific state that's listed on the FDA's notification list is authorizing laboratories within that state to develop and perform COVID-19 tests. And that's done without any submission to FDA. And that specific State Authorization Policy does not apply to the home tests or tests with home specimen collection. Yeah. Just to clarify that exception, it is for LDTs only. It is for LDTs run in high complexity CLIA labs and only for labs that are in the state that the FDA has allowed to do that. And it does not include any testing in the home either, self-collection in the home or a home test of any sort.
SPEAKER QUESTION: Jennifer Stanford
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: COVID test guidance, Home testing exclusion, Lab Developed Tests (LDTs)
REVIEW FLAG: False

QA Block 15-3
CLARIFIED QUESTION: Does the specific State Authorization Policy apply to home tests or tests with home specimen collection?
CLARIFIED ANSWER: The FDA clarified that the State Authorization Policy does not apply to home tests or tests involving home specimen collection.
VERBATIM QUESTION: Does the specific State Authorization Policy apply to home tests or tests with home specimen collection?
VERBATIM ANSWER: That specific State Authorization Policy does not apply to the home tests or tests with home specimen collection.
SPEAKER QUESTION: Jennifer Stanford
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: State Authorization Policy, home tests, home specimen collection
REVIEW FLAG: False

QA Block 15-4
CLARIFIED QUESTION: What factors does the FDA consider when deciding whether to authorize or decline pending EUA submissions?
CLARIFIED ANSWER: The FDA considers a combination of priorities and the review stage when deciding to authorize or decline pending EUA submissions, including whether a submission meets new priorities.
VERBATIM QUESTION: What factors does the FDA consider when deciding whether to authorize or decline pending EUA submissions?
VERBATIM ANSWER: Submissions that are currently pending will remain in the queue until we respond to the developer. So we will be making our way through those to determine whether or not they will proceed towards authorization or whether we will decline to issue. Those decisions will be made based on a combination of the priorities and where they are in the review. Something that's not going to meet the new priorities but was a couple of days away from being authorized, we're probably going to move forward with that. Something that was sort of sitting in the queue and does not meet the priorities, we would have to consider whether there are other factors that would apply there.
SPEAKER QUESTION: Jennifer Stanford
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission decisions, FDA review priorities
REVIEW FLAG: False

QA Block 15-5
CLARIFIED QUESTION: Will tests already in the queue that do not meet the new priorities still be reviewed under any circumstances?
CLARIFIED ANSWER: Pending submissions will be reviewed individually based on priorities and their status in the review process. Tests close to authorization might proceed even if they don't meet new priorities, while others will be evaluated for possible exceptions.
VERBATIM QUESTION: Will tests already in the queue that do not meet the new priorities still be reviewed under any circumstances?
VERBATIM ANSWER: Submissions that are currently pending will remain in the queue until we respond to the developer. So we will be making our way through those to determine whether or not they will proceed towards authorization or whether we will decline to issue. Those decisions will be made based on a combination of the priorities and where they are in the review. Something that's not going to meet the new priorities but was a couple of days away from being authorized, we're probably going to move forward with that. Something that was sort of sitting in the queue and does not meet the priorities, we would have to consider whether there are other factors that would apply there. So you sit tight, if you will. And you will hear an individual decision for each submission that's in-house. The information about those tests that are in queue was really intended to assure that there's not a blanket decision being made on all of the submissions that are in the queue.
SPEAKER QUESTION: Jennifer Stanford
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission review, New guidance priorities, Queue evaluation
REVIEW FLAG: False

QA Block 15-6
CLARIFIED QUESTION: Does the new guidance make individual decisions for each test submission in the queue?
CLARIFIED ANSWER: The FDA will make individual decisions for each EUA submission in the queue, based on priority and review status, rather than applying a blanket decision to all submissions.
VERBATIM QUESTION: Does the new guidance make individual decisions for each test submission in the queue?
VERBATIM ANSWER: Yeah. So submissions that are currently pending will remain in the queue until we respond to the developer. So we will be making our way through those to determine whether or not they will proceed towards authorization or whether we will decline to issue. Those decisions will be made based on a combination of the priorities and where they are in the review. Something that's not going to meet the new priorities but was a couple of days away from being authorized, we're probably going to move forward with that. Something that was sort of sitting in the queue and does not meet the priorities, we would have to consider whether there are other factors that would apply there. So you sit tight, if you will. And you will hear an individual decision for each submission that's in-house. The information about those tests that are in queue was really intended to assure that there's not a blanket decision being made on all of the submissions that are in the queue.
SPEAKER QUESTION: Jennifer Stanford
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submissions, decision process, new guidance
REVIEW FLAG: False

QA Block 15-7
CLARIFIED QUESTION: What specific factors might allow a test submission that does not meet new priorities to still be authorized?
CLARIFIED ANSWER: The FDA may still authorize tests that don't meet new priorities if they are close to authorization or other relevant factors are considered.
VERBATIM QUESTION: What specific factors might allow a test submission that does not meet new priorities to still be authorized?
VERBATIM ANSWER: Something that's not going to meet the new priorities but was a couple of days away from being authorized, we're probably going to move forward with that. Something that was sort of sitting in the queue and does not meet the priorities, we would have to consider whether there are other factors that would apply there.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission prioritization, Authorization exceptions, Pending submissions
REVIEW FLAG: False

QA Block 15-9
CLARIFIED QUESTION: What does the FDA mean by the new policies not encompassing self-collection or at-home tests?
CLARIFIED ANSWER: The FDA's new policies apply only to laboratory-developed tests (LDTs) performed in high-complexity CLIA-certified labs within authorized states. They exclude any at-home tests, including self-collection at home.
VERBATIM QUESTION: What does the FDA mean by the new policies not encompassing self-collection or at-home tests?
VERBATIM ANSWER: Yeah. Just to clarify that exception, it is for LDTs only. It is for LDTs run in high complexity CLIA labs and only for labs that are in the state that the FDA has allowed to do that. And it does not include any testing in the home either, self-collection in the home or a home test of any sort.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: new FDA policies, at-home COVID tests, LDT exclusion
REVIEW FLAG: False


#### 16. Guidance on COVID-19 Test EUA Prioritization

QA Block 16-1
CLARIFIED QUESTION: If we have an EUA application in queue and it's considered prioritized, would FDA still accept brand new pre-EUA submissions?
CLARIFIED ANSWER: FDA will continue communication for tests already in the queue, but these do not necessarily need to go through the pre-EUA process. For directly related cases, contact your reviewer.
VERBATIM QUESTION: If we have an EUA application in queue and it's considered prioritized, would FDA still accept brand new pre-EUA submissions?
VERBATIM ANSWER: If it's related to a test in the queue, then yeah, we'll continue to communicate. It doesn't necessarily have to go through the pre-EUA process, though. If it's directly related to a test that's in the queue, just reach out to your reviewer.
SPEAKER QUESTION: Allen Chun
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA application, pre-EUA process, FDA communication
REVIEW FLAG: False

QA Block 16-2
CLARIFIED QUESTION: Is the pre-EUA submission question specifically for the test that's already in the queue?
CLARIFIED ANSWER: FDA will continue to communicate if it is related to a test already in the queue, but it does not necessarily have to go through the pre-EUA process.
VERBATIM QUESTION: Is the pre-EUA submission question specifically for the test that's already in the queue?
VERBATIM ANSWER: If it's related to a test in the queue, then yeah, we'll continue to communicate. It doesn't necessarily have to go through the pre-EUA process, though.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA process, test queue submissions
REVIEW FLAG: False

QA Block 16-3
CLARIFIED QUESTION: What is the expected communication process with the FDA for tests already in the EUA queue?
CLARIFIED ANSWER: The FDA will continue to communicate if it is related to a test already in the EUA queue, and it does not have to go through the pre-EUA process. Contact your reviewer if it is directly related to the test in the queue.
VERBATIM QUESTION: What is the expected communication process with the FDA for tests already in the EUA queue?
VERBATIM ANSWER: If it's related to a test in the queue, then yeah, we'll continue to communicate. It doesn't necessarily have to go through the pre-EUA process, though. If it's directly related to a test that's in the queue, just reach out to your reviewer.
SPEAKER QUESTION: Allen Chun
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA communication, pre-EUA process
REVIEW FLAG: False

QA Block 16-4
CLARIFIED QUESTION: When is it unnecessary to go through the pre-EUA process for a test related to one already in the queue?
CLARIFIED ANSWER: If a test is directly related to one already in the queue, it is not necessary to go through the pre-EUA process. Communication will continue, and FDA recommends contacting your reviewer.
VERBATIM QUESTION: When is it unnecessary to go through the pre-EUA process for a test related to one already in the queue?
VERBATIM ANSWER: If it's related to a test in the queue, then yeah, we'll continue to communicate. It doesn't necessarily have to go through the pre-EUA process, though.
SPEAKER QUESTION: Allen Chun
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-EUA process, Tests in the queue, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 16-5
CLARIFIED QUESTION: How should developers contact their assigned FDA reviewer for tests in the EUA queue?
CLARIFIED ANSWER: For tests in the EUA queue, developers should contact their assigned FDA reviewer directly.
VERBATIM QUESTION: How should developers contact their assigned FDA reviewer for tests in the EUA queue?
VERBATIM ANSWER: If it's directly related to a test that's in the queue, just reach out to your reviewer.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA tests, FDA communication
REVIEW FLAG: False


#### 17. Using EUA Tests as Comparator Devices for 510(k) Submission

QA Block 17-1
CLARIFIED QUESTION: Would EUA approved multi-panel tests for point of care count as a predicate device for filing a 510k for a multi-panel COVID influenza rapid test?
CLARIFIED ANSWER: FDA clarified that EUA-approved tests cannot serve as predicate devices for 510k submissions but can be used as comparison devices with FDA guidance through a Q-sub or pre-submission.
VERBATIM QUESTION: Would EUA approved multi-panel tests for point of care count as a predicate device for filing a 510k for a multi-panel COVID influenza rapid test?
VERBATIM ANSWER: So the predicate device has to be something that FDA cleared. And that's just the formality of the submission. I think what you're talking about is a comparison device. The current predicate may not serve well as a comparator. And that's why we have expressed flexibility in using EUA authorized tests as a comparator. However, we do recommend that you check in with the FDA through a Q-sub or pre-submission to make sure that the comparator is appropriate for your test. Not all EUA authorized tests may be appropriate. And so that will reduce your risk of doing a study if you go ahead and are assured of that and any other questions you might have about your development of your test for submission.
SPEAKER QUESTION: Rohit Polavarapu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA-approved tests, 510k submission, FDA guidance
REVIEW FLAG: False

QA Block 17-4
CLARIFIED QUESTION: What factors determine whether an EUA authorized test is an appropriate comparator?
CLARIFIED ANSWER: FDA recommends consulting through a Q-sub or pre-submission to ensure that an EUA authorized test is an appropriate comparator. Not all EUA authorized tests are suitable, and prior confirmation can help reduce study risks.
VERBATIM QUESTION: What factors determine whether an EUA authorized test is an appropriate comparator?
VERBATIM ANSWER: The current predicate may not serve well as a comparator. And that's why we have expressed flexibility in using EUA authorized tests as a comparator. However, we do recommend that you check in with the FDA through a Q-sub or pre-submission to make sure that the comparator is appropriate for your test. Not all EUA authorized tests may be appropriate. And so that will reduce your risk of doing a study if you go ahead and are assured of that and any other questions you might have about your development of your test for submission. Kris, anything to add to what I've responded?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorized tests, Comparator selection, Q-sub or pre-submission
REVIEW FLAG: False

QA Block 17-5
CLARIFIED QUESTION: What are the three options for comparators that can be considered for submissions?
CLARIFIED ANSWER: FDA has at least three options for comparators that can be considered, and they recommend submitting a Q-sub or pre-sub for guidance.
VERBATIM QUESTION: What are the three options for comparators that can be considered for submissions?
VERBATIM ANSWER: If you do submit a Q-sub or pre-sub, we can respond to you with your comparator question. Just to let you know, there are-- I would say I think we have at least three options for comparators that you can consider.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: comparator options, FDA submission guidance
REVIEW FLAG: False

QA Block 17-6
CLARIFIED QUESTION: How should developers utilize Q-submissions or pre-submissions to verify their comparator choice?
CLARIFIED ANSWER: FDA recommends using a Q-submission or pre-submission to ensure your comparator choice is appropriate, reducing study risks. Not all EUA-authorized tests qualify as comparators.
VERBATIM QUESTION: How should developers utilize Q-submissions or pre-submissions to verify their comparator choice?
VERBATIM ANSWER: The current predicate may not serve well as a comparator. And that's why we have expressed flexibility in using EUA authorized tests as a comparator. However, we do recommend that you check in with the FDA through a Q-sub or pre-submission to make sure that the comparator is appropriate for your test. Not all EUA authorized tests may be appropriate. And so that will reduce your risk of doing a study if you go ahead and are assured of that and any other questions you might have about your development of your test for submission.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Q-submission, comparator device, EUA tests
REVIEW FLAG: False


#### 18. De Novo Submissions and EUA Validation Process Guidance

QA Block 18-1
CLARIFIED QUESTION: If we decide to transition our EUA application to a formal process such as de novo, do we need to start all the validation over, or can we leverage the validation already completed?
CLARIFIED ANSWER: FDA allows developers to leverage already reviewed EUA data for a full submission, including de novo pathways.
VERBATIM QUESTION: If we decide to transition our EUA application to a formal process such as de novo, do we need to start all the validation over, or can we leverage the validation already completed?
VERBATIM ANSWER: So anybody who has an EUA authorization or has an EUA submission in that can be reviewed, that data, especially if it's ultimately authorized, can be used for the full submission. And we haven't authorized an antigen test now. So the submissions now are going to be de novo submissions until we grant the first de novo. And then submissions after that date can be 510ks. But yeah, we are seeking for developers to fully utilize the EUA data that was reviewed by the FDA and successfully reviewed by the FDA.
SPEAKER QUESTION: Homer Wu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA to de novo transition, EUA data reuse
REVIEW FLAG: False

QA Block 18-2
CLARIFIED QUESTION: If there are multiple companies applying for de novo, does the FDA approve multiple companies for de novo?
CLARIFIED ANSWER: The FDA grants the first de novo authorization. Subsequent authorizations for similar submissions are cleared as 510(k).
VERBATIM QUESTION: If there are multiple companies applying for de novo, does the FDA approve multiple companies for de novo?
VERBATIM ANSWER: The first authorization will be a de novo grant. And the subsequent authorizations will be a clearance, so those that have a de novo submission in house right now. Or have or have one prior to the first granting.
SPEAKER QUESTION: Homer Wu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: de novo process, FDA authorization rules
REVIEW FLAG: False

QA Block 18-3
CLARIFIED QUESTION: If we apply for de novo and it gets approved, but someone else submits before us, will their application always result in a 510k clearance?
CLARIFIED ANSWER: If someone submits a de novo application before yours is approved, their application will result in a 510k clearance if yours is approved first.
VERBATIM QUESTION: If we apply for de novo and it gets approved, but someone else submits before us, will their application always result in a 510k clearance?
VERBATIM ANSWER: It would be a 510k clearance.
SPEAKER QUESTION: Homer Wu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: de novo approval, 510k clearance
REVIEW FLAG: False

QA Block 18-4
CLARIFIED QUESTION: How can developers fully utilize EUA data that was reviewed and approved by the FDA for a full submission?
CLARIFIED ANSWER: Developers who have EUA authorization or submissions can use reviewed and authorized data for full submissions. FDA encourages developers to fully utilize successfully reviewed EUA data.
VERBATIM QUESTION: How can developers fully utilize EUA data that was reviewed and approved by the FDA for a full submission?
VERBATIM ANSWER: So anybody who has an EUA authorization or has an EUA submission in that can be reviewed, that data, especially if it's ultimately authorized, can be used for the full submission. And we haven't authorized an antigen test now. So the submissions now are going to be de novo submissions until we grant the first de novo. And then submissions after that date can be 510ks. But yeah, we are seeking for developers to fully utilize the EUA data that was reviewed by the FDA and successfully reviewed by the FDA.
SPEAKER QUESTION: Homer Wu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA data utilization, Full submission protocols, FDA submission pathways
REVIEW FLAG: False

QA Block 18-5
CLARIFIED QUESTION: What is the process or recommendation for submitting a pre-submission (Q-sub) to achieve full authorization for a COVID test?
CLARIFIED ANSWER: FDA recommends submitting a pre-submission (Q-sub) for those seeking full authorization for their COVID test.
VERBATIM QUESTION: What is the process or recommendation for submitting a pre-submission (Q-sub) to achieve full authorization for a COVID test?
VERBATIM ANSWER: And if you haven't already submitted a pre-submission or a Q-sub, we do recommend that for those that are trying to achieve full authorization for their COVID test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-submission (Q-sub), Full authorization, COVID test process
REVIEW FLAG: False

QA Block 18-6
CLARIFIED QUESTION: What steps should be followed when transitioning from EUA to de novo submission?
CLARIFIED ANSWER: FDA advises utilizing EUA data already reviewed and successfully reviewed for de novo submissions. Current submissions will remain de novo until the first de novo is granted, after which subsequent submissions may follow the 510k pathway.
VERBATIM QUESTION: What steps should be followed when transitioning from EUA to de novo submission?
VERBATIM ANSWER: So anybody who has an EUA authorization or has an EUA submission in that can be reviewed, that data, especially if it's ultimately authorized, can be used for the full submission. And we haven't authorized an antigen test now. So the submissions now are going to be de novo submissions until we grant the first de novo. And then submissions after that date can be 510ks. But yeah, we are seeking for developers to fully utilize the EUA data that was reviewed by the FDA and successfully reviewed by the FDA.
SPEAKER QUESTION: Homer Wu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA to de novo transition, data utilization, submission process
REVIEW FLAG: False

QA Block 18-7
CLARIFIED QUESTION: What specific data from an EUA submission can be used in a de novo submission or 510k clearance?
CLARIFIED ANSWER: Data reviewed and successfully authorized under an EUA, especially for tests ultimately authorized, can be used for full submissions like de novo or 510k clearances.
VERBATIM QUESTION: What specific data from an EUA submission can be used in a de novo submission or 510k clearance?
VERBATIM ANSWER: So anybody who has an EUA authorization or has an EUA submission in that can be reviewed, that data, especially if it's ultimately authorized, can be used for the full submission. And we haven't authorized an antigen test now. So the submissions now are going to be de novo submissions until we grant the first de novo. And then submissions after that date can be 510ks. But yeah, we are seeking for developers to fully utilize the EUA data that was reviewed by the FDA and successfully reviewed by the FDA.
SPEAKER QUESTION: Homer Wu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA data usage, de novo submissions, 510k clearances
REVIEW FLAG: False

QA Block 18-8
CLARIFIED QUESTION: How is the FDA distinguishing between de novo and 510k submissions for COVID-19 tests after the first de novo grant?
CLARIFIED ANSWER: COVID-19 test submissions are de novo until the first de novo grant is issued. After that, subsequent submissions can fall under the 510k pathway.
VERBATIM QUESTION: How is the FDA distinguishing between de novo and 510k submissions for COVID-19 tests after the first de novo grant?
VERBATIM ANSWER: And we haven't authorized an antigen test now. So the submissions now are going to be de novo submissions until we grant the first de novo. And then submissions after that date can be 510ks.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: de novo vs 510k, COVID-19 test submissions
REVIEW FLAG: False

### removed qa blocks
QA Block 5-1
CLARIFIED QUESTION: Will the FDA require additional clinical study results under an EUA for serial testing recommendations with at-home COVID-19 antigen tests?
CLARIFIED ANSWER: The FDA is unlikely to request additional studies for serial testing under an EUA as it plans to use data from the NIH-supported UMass study. For 510k clearance, a pre-submission to discuss clinical validation strategies is recommended.
VERBATIM QUESTION: Will the FDA require additional clinical study results under an EUA for serial testing recommendations with at-home COVID-19 antigen tests?
VERBATIM ANSWER: FDA continues to work to reflect the need for serial testing in antigen test authorizations. The results of the NIH-supported UMass study have been published. And FDA plans to use this data in support of serial testing claims. One of the goals of the study was to provide broadly applicable data to avoid the need for individual developers to perform large and expensive tests-- or expensive studies, rather. And so at this time, the FDA is not likely to request additional studies to support serial testing under EUA. And as I noted previously, we do continue to recommend submitting a pre-submission to discuss your proposed clinical validation strategies if you intend to pursue a 510k.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA requirements for serial testing, NIH study data for at-home antigen tests, 510k clinical validation
REVIEW FLAG: False

QA Block 8-1
CLARIFIED QUESTION: What is meant by a successful EUA request?
CLARIFIED ANSWER: A successful EUA request means being issued an EUA following submission of the EUA request.
VERBATIM QUESTION: What is meant by a successful EUA request?
VERBATIM ANSWER: It's a similar language in both guidances I believe at this point. So a successful EUA request would be having been issued an EUA following submission of an EUA request.
SPEAKER QUESTION: Ashanti Brown
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: successful EUA request, COVID-19 diagnostics policy
REVIEW FLAG: False

QA Block 9-1
CLARIFIED QUESTION: Does the FDA accept clinical study data from outside of the US for point of care devices for monkeypox?
CLARIFIED ANSWER: FDA indicates it is possible to accept clinical study data from outside the US for monkeypox devices, but challenges exist due to the unavailability of necessary comparator tests. FDA recommends submitting a pre-EUA for specific questions.
VERBATIM QUESTION: Does the FDA accept clinical study data from outside of the US for point of care devices for monkeypox?
VERBATIM ANSWER: That's possible. The comparator tests that the FDA recognizes at the moment is the CDC NVO orthopox test that is FDA cleared. So I don't believe that that's available for this kind of study. So that would be the challenge with that. But I think this is a very specific question. And you can come in with a pre-EUA for that question.
SPEAKER QUESTION: Niya Su
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA data acceptance, clinical study data, monkeypox diagnostics
REVIEW FLAG: False

QA Block 11-6
CLARIFIED QUESTION: Under what circumstances should developers submit a pre-EUA application to determine qualification as a novel technology?
CLARIFIED ANSWER: Developers should submit a pre-EUA application to determine if their technology qualifies as a novel technology under the outlined exceptions.
VERBATIM QUESTION: Under what circumstances should developers submit a pre-EUA application to determine qualification as a novel technology?
VERBATIM ANSWER: You can come in for a pre-EUA submission to ask if your technology would be likely to qualify under that novel technology exception.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA application, novel technology, COVID-19 testing
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: Does the Agency have any additional recommendations to strengthen risk controls associated with over-the-counter, visually read, multianalyte antigen tests labeled for symptomatic users only?
CLARIFIED ANSWER: 
VERBATIM QUESTION: Does the Agency have any additional recommendations to strengthen risk controls associated with over-the-counter, visually read, multianalyte antigen tests labeled for symptomatic users only?
VERBATIM ANSWER: NO RELEVANT ANSWER IN TRANSCRIPT
SPEAKER QUESTION: Ling Koh
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 
REVIEW FLAG: False
NOTES: While Toby Lowe clarified the definition of over-the-counter vs prescription, the specific question about additional risk control recommendations was not addressed.

QA Block 15-8
CLARIFIED QUESTION: Are home collection or home testing products excluded from the State Authorization Policy?
CLARIFIED ANSWER: The State Authorization Policy does not apply to home tests or tests involving home specimen collection.
VERBATIM QUESTION: Are home collection or home testing products excluded from the State Authorization Policy?
VERBATIM ANSWER: I think you may have misread that. I think the language that you're referring to, that it does not apply to home tests, was specifically on the slide about the State Authorization Policy. So that is only for that policy where a specific state that's listed on the FDA's notification list is authorizing laboratories within that state to develop and perform COVID-19 tests. And that's done without any submission to FDA. And that specific State Authorization Policy does not apply to the home tests or tests with home specimen collection.
SPEAKER QUESTION: Jennifer Stanford
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: State Authorization Policy, Home testing exclusion, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 17-2
CLARIFIED QUESTION: Would the currently EUA approved multi-panel tests count as a predicate device?
CLARIFIED ANSWER: EUA-approved tests cannot serve as predicate devices, as predicates must be FDA-cleared. However, EUA-authorized tests may serve as comparators with FDA approval through a Q-sub or pre-submission process.
VERBATIM QUESTION: Would the currently EUA approved multi-panel tests count as a predicate device?
VERBATIM ANSWER: So the predicate device has to be something that FDA cleared. And that's just the formality of the submission. I think what you're talking about is a comparison device. The current predicate may not serve well as a comparator. And that's why we have expressed flexibility in using EUA authorized tests as a comparator. However, we do recommend that you check in with the FDA through a Q-sub or pre-submission to make sure that the comparator is appropriate for your test. Not all EUA authorized tests may be appropriate. And so that will reduce your risk of doing a study if you go ahead and are assured of that and any other questions you might have about your development of your test for submission.
SPEAKER QUESTION: Rohit Polavarapu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA-approved tests, 510k submission, comparator devices
REVIEW FLAG: False

QA Block 17-3
CLARIFIED QUESTION: What are the FDA's recommendations for using EUA authorized tests as comparators?
CLARIFIED ANSWER: FDA allows the use of EUA authorized tests as comparators but recommends confirming their appropriateness through a Q-sub or pre-submission process to minimize risks.
VERBATIM QUESTION: What are the FDA's recommendations for using EUA authorized tests as comparators?
VERBATIM ANSWER: The current predicate may not serve well as a comparator. And that's why we have expressed flexibility in using EUA authorized tests as a comparator. However, we do recommend that you check in with the FDA through a Q-sub or pre-submission to make sure that the comparator is appropriate for your test. Not all EUA authorized tests may be appropriate. And so that will reduce your risk of doing a study if you go ahead and are assured of that and any other questions you might have about your development of your test for submission.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorized tests, comparator device, FDA recommendations
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-05 07:53:22 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 18
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What are the steps required for monkeypox LDT developers to notify the FDA by the October 13 deadline?
QI 1-2: Are there circumstances where an EUA request is not expected for monkeypox diagnostic tests?
QI 1-3: What is the FDA's enforcement discretion policy for monkeypox LDTs after the EUA test declaration?
QI 1-4: What are the appropriate uses of the CDC-cleared NVO orthopox assay for validating monkeypox tests?
QI 1-5: Can laboratories provide leftover CDC NVO assay tested samples for validation purposes?
QI 1-6: Are test developers allowed to request new clinical samples to be tested with the CDC assay for validation purposes?
QI 1-7: What should developers know about the recent updates to the COVID test policy guidance issued on September 27th?
QI 1-8: Which types of COVID-19 diagnostic tests are now prioritized for EUA review by the FDA?
QI 1-9: What does the FDA recommend for developers considering the traditional premarket review pathway?
QI 1-10: What is the distinction between EUA statutory requirements and traditional premarket approval requirements?
QI 1-11: What are the conditions under which modified COVID-19 diagnostic tests require a new EUA or traditional authorization?
QI 1-12: For ongoing EUA reviews, how does the FDA handle unauthorized COVID-19 diagnostic tests already being marketed or distributed?
QI 1-13: What is the FDA's policy for high-complexity CLIA labs making validated modifications to an existing authorized COVID-19 test?
QI 1-14: When and how should developers cease distribution or marketing if their EUA request is declined by the FDA?

#### Section 2 of 18
##### Explicit Questions Extraction
QE 2-1: Can monkeypox diagnostic test developers inform FDA of their intent to submit an EUA request without providing a timeline for completion of validation studies and submission of an EUA request?

##### Implicit Questions Extraction
QI 2-1: What should be done if a developer's question sent via email to FDA is not answered during the town hall?
QI 2-2: What type of information is recommended to include in an intent to submit an EUA request for a diagnostic test?
QI 2-3: What is the difference between FDA's recommendations and requirements for EUA submissions?
QI 2-4: How does including preliminary information in an email to FDA help with prioritization of EUA requests?

#### Section 3 of 18
##### Explicit Questions Extraction
QE 3-1: Is FDA considering multiplex antigen tests that can detect a combination of viruses, such as SARS-CoV-2 and influenza, for use in an over-the-counter setting for symptomatic users only?

##### Implicit Questions Extraction
QI 3-1: What does the FDA recommend for developers preparing to submit over-the-counter multianalyte antigen tests for authorization?
QI 3-2: Are there specific guidance updates that developers should review before pursuing a pre-submission for over-the-counter multianalyte tests?
QI 3-3: Does the FDA provide templates or specific recommendations for multianalyte diagnostic tests that integrate home-collected specimens?

#### Section 4 of 18
##### Explicit Questions Extraction
QE 4-1: To support 510(k) for COVID-19 rapid tests, is FDA requiring serial testing as part of the clinical performance study for symptomatic individuals?

##### Implicit Questions Extraction
QI 4-1: What are the recommended clinical validation strategies for pursuing a 510k for COVID-19 rapid antigen tests?
QI 4-2: Does the FDA's recommendation for serial testing apply to all rapid antigen tests or only specific types?
QI 4-3: When will the FDA update the templates to reflect the new recommendations regarding serial testing?
QI 4-4: What is the de novo pathway status for COVID-19 rapid antigen tests and why has one not yet been granted?
QI 4-5: What details are included in the August safety communication mentioned regarding serial testing recommendations?

#### Section 5 of 18
##### Explicit Questions Extraction
QE 5-1: Will the FDA require additional clinical study results under an EUA for serial testing recommendations with at-home COVID-19 antigen tests?
QE 5-2: Will the FDA require additional clinical study results under a 510k for serial testing recommendations with at-home COVID-19 antigen tests?
QE 5-3: Is the right to reference the NIH-supported UMass study sufficient for serial testing claims without conducting additional clinical studies?

##### Implicit Questions Extraction
QI 5-1: How will the FDA integrate the NIH-Utsupported UMass study data into the authorization of at-home COVID-19 antigen tests?
QI 5-2: Does the FDA recommend a pre-submission process to discuss clinical validation strategies even if developers are utilizing the NIH-supported UMass study data?
QI 5-3: Can developers entirely bypass conducting clinical studies if their labeling aligns with the NIH-supported UMass study data and FDA guidance?

#### Section 6 of 18
##### Explicit Questions Extraction
QE 6-1: To support an at-home testing claim, in a clinical study where the comparator is not being used as the standard of care, does FDA recommend that clinical study subjects swab themselves and perform the test before the comparator swab is taken, in order to not train or mislead the lay tester?

##### Implicit Questions Extraction

#### Section 7 of 18
##### Explicit Questions Extraction
QE 7-1: Can you clarify if the pre-EUAs that have already been submitted and are under review prior to this announcement will still remain in the queue?
QE 7-2: Should test developers with pending pre-EUAs convert those into a Q-sub or pre-sub submission to the FDA if the test does not meet the conditions for continued EUA review?
QE 7-3: Should we reach out to our pre-EUA reviewer to see if the review is still ongoing, or should we just wait?

##### Implicit Questions Extraction
QI 7-1: What differentiates a pre-EUA from an actual EUA submission in terms of regulatory purpose and use during the COVID-19 pandemic?
QI 7-2: Under what conditions would a pre-EUA submission qualify for continued EUA review given the new priorities?
QI 7-3: If a pre-EUA does not meet the criteria for continued review, what are the specific steps to convert it to a Q-sub or pre-submission?
QI 7-4: How will the FDA communicate to sponsors whether their submission is being reviewed or closed without feedback, based on new priorities?
QI 7-5: What criteria determine whether a COVID-19 diagnostic test submission remains in the queue or is deprioritized?

#### Section 8 of 18
##### Explicit Questions Extraction
QE 8-1: What is meant by a successful EUA request?
QE 8-2: Does a successful EUA request include the actual EUA approval and/or pre-EUA interactions?
QE 8-3: Can you elaborate on what a similar experience would be for an experienced developer?

##### Implicit Questions Extraction

#### Section 9 of 18
##### Explicit Questions Extraction
QE 9-1: Does the FDA accept clinical study data from outside of the US for point of care devices for monkeypox?
QE 9-2: Does the FDA accept clinical study data from outside of the US for high throughput devices for high complexity labs for monkeypox?

##### Implicit Questions Extraction
QI 9-1: What comparator tests does the FDA recommend for clinical studies on monkeypox diagnostics?
QI 9-2: Is the CDC NVO orthopox test available outside of the US for use in comparative studies?
QI 9-3: What steps are needed to submit a pre-EUA related to monkeypox diagnostic tests?

#### Section 10 of 18
##### Explicit Questions Extraction
QE 10-1: For the EUA of antigen COVID-19 at-home test kits, how many positive, negative, and asymptomatic samples are recommended for the 510(k) submission pathway instead of the EUA?

##### Implicit Questions Extraction
QI 10-1: What is the process for obtaining FDA recommendations specific to 510(k) submissions for antigen COVID-19 at-home test kits?
QI 10-2: Does the FDA provide guidance for the number of positive, negative, and asymptomatic samples required for the 510(k) submission pathway?
QI 10-3: How does the Q-Sub or Pre-Sub process facilitate access to guidelines for COVID-19 antigen tests?
QI 10-4: Are the prepared recommendations for antigen tests specific to at-home test kits or applicable to all antigen tests?

#### Section 11 of 18
##### Explicit Questions Extraction
QE 11-1: Can you elaborate on and provide more examples of the meaning of new technologies and fulfilling an unmet need in the context of the COVID-19 re-prioritization policy?
QE 11-2: In the context of COVID-19 diagnostics, can a company submit a pre-EUA submission to determine if their technology would qualify as a novel technology?

##### Implicit Questions Extraction
QI 11-1: What constitutes a 'me too' product in the context of COVID-19 re-prioritization policy?
QI 11-2: Is the FDA currently open to accepting additional submissions for breath tests as a novel technology?
QI 11-3: Will the FDA update the policy if the number of breath tests reaches a saturation point?
QI 11-4: Under what circumstances should developers submit a pre-EUA application to determine qualification as a novel technology?

#### Section 12 of 18
##### Explicit Questions Extraction
QE 12-1: When can test developers expect to receive guidance regarding the studies referenced in the safety communication for at-home COVID-19 antigen tests and recommended labeling changes?

##### Implicit Questions Extraction

#### Section 13 of 18
##### Explicit Questions Extraction
QE 13-1: Does the Agency mean that over-the-counter multianalyte antigen tests are non-prescription, for example, for a test that's visually read, does not have a companion app, but is labeled for symptomatic users only?
QE 13-2: Does the Agency have any additional recommendations to strengthen risk controls associated with over-the-counter, visually read, multianalyte antigen tests labeled for symptomatic users only?

##### Implicit Questions Extraction

#### Section 14 of 18
##### Explicit Questions Extraction
QE 14-1: Is interpretation of a low positive result required for usability comprehension studies involving COVID tests?
QE 14-2: Are you referring to a COVID antigen test read by a lay user and differentiating between usability and user comprehension?

##### Implicit Questions Extraction
QI 14-1: What are the FDA recommendations for designing usability and user comprehension studies for over-the-counter COVID antigen tests?
QI 14-2: Should faint lines on COVID antigen tests specifically be included when evaluating user comprehension and usability?
QI 14-3: Are there preferred ways to ensure over-the-counter COVID tests are easy to interpret by lay users, such as the brightness or darkness of test result lines?

#### Section 15 of 18
##### Explicit Questions Extraction
QE 15-1: Will the new EUA guidance apply to submissions already in the queue or only to new EUA submissions?
QE 15-2: Does the new guidance apply to over-the-counter COVID home testing in addition to lab-developed tests?
QE 15-3: Does the specific State Authorization Policy apply to home tests or tests with home specimen collection?

##### Implicit Questions Extraction
QI 15-1: What factors does the FDA consider when deciding whether to authorize or decline pending EUA submissions?
QI 15-2: Will tests already in the queue that do not meet the new priorities still be reviewed under any circumstances?
QI 15-3: Does the new guidance make individual decisions for each test submission in the queue?
QI 15-4: What specific factors might allow a test submission that does not meet new priorities to still be authorized?
QI 15-5: Are home collection or home testing products excluded from the State Authorization Policy?
QI 15-6: What does the FDA mean by the new policies not encompassing self-collection or at-home tests?

#### Section 16 of 18
##### Explicit Questions Extraction
QE 16-1: If we have an EUA application in queue and it's considered prioritized, would FDA still accept brand new pre-EUA submissions?
QE 16-2: Is the pre-EUA submission question specifically for the test that's already in the queue?

##### Implicit Questions Extraction
QI 16-1: What is the expected communication process with the FDA for tests already in the EUA queue?
QI 16-2: When is it unnecessary to go through the pre-EUA process for a test related to one already in the queue?
QI 16-3: How should developers contact their assigned FDA reviewer for tests in the EUA queue?

#### Section 17 of 18
##### Explicit Questions Extraction
QE 17-1: Would EUA approved multi-panel tests for point of care count as a predicate device for filing a 510k for a multi-panel COVID influenza rapid test?
QE 17-2: Would the currently EUA approved multi-panel tests count as a predicate device?

##### Implicit Questions Extraction
QI 17-1: What are the FDA's recommendations for using EUA authorized tests as comparators?
QI 17-2: What factors determine whether an EUA authorized test is an appropriate comparator?
QI 17-3: What are the three options for comparators that can be considered for submissions?
QI 17-4: How should developers utilize Q-submissions or pre-submissions to verify their comparator choice?

#### Section 18 of 18
##### Explicit Questions Extraction
QE 18-1: If we decide to transition our EUA application to a formal process such as de novo, do we need to start all the validation over, or can we leverage the validation already completed?
QE 18-2: If there are multiple companies applying for de novo, does the FDA approve multiple companies for de novo?
QE 18-3: If we apply for de novo and it gets approved, but someone else submits before us, will their application always result in a 510k clearance?

##### Implicit Questions Extraction
QI 18-1: How can developers fully utilize EUA data that was reviewed and approved by the FDA for a full submission?
QI 18-2: What is the process or recommendation for submitting a pre-submission (Q-sub) to achieve full authorization for a COVID test?
QI 18-3: What steps should be followed when transitioning from EUA to de novo submission?
QI 18-4: What specific data from an EUA submission can be used in a de novo submission or 510k clearance?
QI 18-5: How is the FDA distinguishing between de novo and 510k submissions for COVID-19 tests after the first de novo grant?
